TAPUR STUDY: PARTICIPANTS RECEIVE ABEMACICLIB – DOSAGE, FREQUENCY AND DURATION PER LABEL; ACCEPTABLE GENOMIC MATCHES INCLUDE CDK4 AMPLIFICATION
This phase 2 study is a nonrandomized, open label study enrolling patients of all tumor types, including soft tissue sarcomas. One of the study arms investigates the study drug abemaciclib (Verzenio), an oral targeted therapy, for patients who are no longer benefitting from standard treatment, and whose tumor has a CDK4 amplification. The Targeted Agent and Profiling Utilization Registry (TAPUR) Study is a non-randomized clinical trial that aims to describe the safety and efficacy of commercially available, targeted anticancer drugs prescribed for treatment of patients with advanced cancer that has a potentially actionable genomic variant. TAPUR will study Food and Drug Administration (FDA)-approved targeted therapies that are contributed by collaborating pharmaceutical companies, catalogue the choice of molecular profiling test by clinical oncologists and develop hypotheses for additional clinical trials.
There are over 250 clinical sites across 28 states in the United States. For more information on the TAPUR Study, visit the TAPUR website at www.TAPUR.org. If you would like to learn more, the study team recently held a virtual live Grand Rounds which was recorded. The May 2023 TAPUR Grand Rounds recording is available for viewing and can be found under the “Study Results” page of the TAPUR website.
ClinicalTrials.gov: https://clinicaltrials.gov/study/NCT02693535
Sponsor website: www.TAPUR.org